Department of Hematology, The Affiliated Hospital of Nantong University, Nantong, People's Republic of China.
Department of Oncology, Affiliated Tumor Hospital of Nantong University, Nantong, People's Republic of China.
Hematology. 2020 Dec;25(1):457-463. doi: 10.1080/16078454.2020.1850973.
Bone destruction and renal impairment are two frequent complications of multiple myeloma (MM). Cystatin C, an extracellular cysteine proteinase inhibitor, is encoded by the housekeeping gene CST3 and associated with human tumors. The role of cystatin C in multiple myeloma has been revealed recently. The purpose of this study was to explore the role of cystatin C as a proteasome inhibitor in multiple myeloma. A comprehensive literature review was conducted through Pubmed to summarize the published evidence on cystatin C in multiple myeloma. English literature sources since 1999 were searched, using the terms cystatin C, multiple myeloma. cystatin C is a sensitive indicator for the diagnosis of myeloma nephropathy and has a dual role in myeloma bone disease. Also, cystatin C reflects tumor burden and is strongly associated with prognosis in patients with multiple myeloma. Cystatin C have great diagnostic and prognostic value in multiple myeloma. It can provide a new treatment direction for MM by designing and searching for antagonists of cystatin C or cysteine protease agonists using cystatin C as a therapeutic target.
骨破坏和肾功能损害是多发性骨髓瘤（MM）的两种常见并发症。胱抑素 C 是一种细胞外半胱氨酸蛋白酶抑制剂，由管家基因 CST3 编码，与人类肿瘤有关。胱抑素 C 在多发性骨髓瘤中的作用最近已经被揭示。本研究旨在探讨胱抑素 C 作为蛋白酶体抑制剂在多发性骨髓瘤中的作用。通过 Pubmed 进行了全面的文献综述，总结了胱抑素 C 在多发性骨髓瘤中的已发表证据。搜索了自 1999 年以来的英文文献来源，使用的术语有胱抑素 C、多发性骨髓瘤。胱抑素 C 是诊断骨髓瘤肾病的敏感指标，在骨髓瘤骨病中具有双重作用。此外，胱抑素 C 反映肿瘤负荷，与多发性骨髓瘤患者的预后密切相关。胱抑素 C 在多发性骨髓瘤中有很大的诊断和预后价值。通过设计和搜索胱抑素 C 的拮抗剂或半胱氨酸蛋白酶激动剂，将胱抑素 C 作为治疗靶点，可能为 MM 提供新的治疗方向。
